MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$3,200K
EPS
$0.07
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2024-12-31
2024-09-30
2024-06-30
Revenues
0 41 42 57
Cost of revenue
0 41 42 48
Gross profit
0 0 0 9
Research and development expense
1,643 968 1,477 1,086
General and administrative expense
1,613 1,232 1,544 1,088
Net expenses related to opko collaboration agreement
3,256 2,200 3,021 2,174
Operating loss
-3,256 -2,199 -3,021 -2,165
Financial income, net
56 13 -20
Income (loss) from continuing operations before income taxes, noncontrolling interest
--2,169 -3,021 -
Income tax expense (benefit)
-4 --
Net loss
-3,200 -2,187 -3,021 -2,145
Earnings per share, basic and diluted
0.07 0.055 0.08 0.06
Earnings per share, diluted
0.07 0.055 0.08 0.06
Weighted average number of shares outstanding, basic and diluted
47,089,814 -18,542,296.5 37,644,612 37,090,160
Weighted average number of shares outstanding, diluted
47,089,814 -18,542,296.5 37,644,612 37,090,160
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$3,200K Financial income, net$56K Operating loss-$3,256K Net expensesrelated to opko...$3,256K General andadministrative expense$1,613K Research and developmentexpense$1,643K

Entera Bio Ltd. (ENTX)

Entera Bio Ltd. (ENTX)